Trials / Completed
CompletedNCT00859482
Differential Immune Effects of Natalizumab
A Phase IV Study to Investigate Differential Immune Effects of Natalizumab
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 27 (actual)
- Sponsor
- Cantonal Hospital of St. Gallen · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS). A blockade of VLA-4 with natalizumab may not only interfere with autoimmunological processes but also with central nervous system (CNS) immune surveillance.
Detailed description
Longitudinal ex vivo and in vitro study to determine the effect of natalizumab on frequency of distinct immune cells and on the frequency and suppressive function of natural CD4+CD25+ regulatory T cells (Tregs).
Conditions
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2009-03-11
- Last updated
- 2009-03-11
Source: ClinicalTrials.gov record NCT00859482. Inclusion in this directory is not an endorsement.